In AML, IGF2BP2 regulates key targets in the glutamine metabolic pathway (e.g., MYC, GPT1, and SLC5A6) in a m6A-dependent manner, promoting the development and self-renewal of leukemia stem/initiation cells. This evidence concerns the gene IGF2BP2 and acute myeloid leukemia.